Sex: U
Vaccine: COVID19-2
Symptoms: No adverse event, Wrong product administered
Clinical narrative: No adverse event; All doses were given at a 0.2mL dosage from the presentation with the dark pink cap with yellow border instead of the dark blue cap and label with gray border presentation; This spontaneous case was reported by a consumer and describes the occurrence of WRONG PRODUCT ADMINISTERED (All doses were given at a 0.2mL dosage from the presentation with the dark pink cap with yellow border instead of the dark blue cap and label with gray border presentation) and NO ADVERSE EVENT (No adverse event) in a child patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 215K22A) for COVID-19 prophylaxis.     The patient did not received any other vaccines in the 4 weeks prior to COVID-19 vaccine.     In April 2023, the patient received first dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) .2 milliliter. In April 2023, the patient experienced WRONG PRODUCT ADMINISTERED (All doses were given at a 0.2mL dosage from the presentation with the dark pink cap with yellow border instead of the dark blue cap and label with gray border presentation). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, WRONG PRODUCT ADMINISTERED (All doses were given at a 0.2mL dosage from the presentation with the dark pink cap with yellow border instead of the dark blue cap and label with gray border presentation) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for WRONG PRODUCT ADMINISTERED (All doses were given at a 0.2mL dosage from the presentation with the dark pink cap with yellow border instead of the dark blue cap and label with gray border presentation).    No concomitant medications were provided. Doses were administered from 24-Apr-2023 to 28-Apr-2023. Patients between 6m-5y of age were involved.  No reported symptoms. No treatment medication was provided. This case contains information for the 1st of 12 child patients described by the reporter.   This case was linked to US-MODERNATX, INC.-MOD-2023-722129, US-MODERNATX, INC.-MOD-2023-722131, US-MODERNATX, INC.-MOD-2023-722132, US-MODERNATX, INC.-MOD-2023-722133, US-MODERNATX, INC.-MOD-2023-722134, US-MODERNATX, INC.-MOD-2023-722136, US-MODERNATX, INC.-MOD-2023-722148, US-MODERNATX, INC.-MOD-2023-722150, US-MODERNATX, INC.-MOD-2023-722147, US-MODERNATX, INC.-MOD-2023-722146, US-MODERNATX, INC.-MOD-2023-722149 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-722134:(patient 6) US-MODERNATX, INC.-MOD-2023-722131:(patient 3) US-MODERNATX, INC.-MOD-2023-722129:(patient 2) US-MODERNATX, INC.-MOD-2023-722132:(patient 4) US-MODERNATX, INC.-MOD-2023-722133:(patient 5) US-MODERNATX, INC.-MOD-2023-722147:patient no. 10 US-MODERNATX, INC.-MOD-2023-722146:patient no. 11 US-MODERNATX, INC.-MOD-2023-722150:patient no. 09 US-MODERNATX, INC.-MOD-2023-722136:patient no. 7 US-MODERNATX, INC.-MOD-2023-722149:patient no. 12 US-MODERNATX, INC.-MOD-2023-722148:patient no. 08